Literature DB >> 20838755

[Percutaneous administration of recombinant human bone morphogenetic protein-7 (rhBMP-7) after callus distraction. Two case reports].

F Högel1, M Militz, V Bühren, P Augat, F Wagner.   

Abstract

Two cases of increased bone density after callus distraction are described following percutaneous administration of 3.5 mg recombinant bone morphogenetic protein-7 (rhBMP-7). Both patients underwent segmental resection and segmental transport for osteomyelitis of the long bones (femur and tibia) but no callus maturation occurred. After percutaneous administration of rhBMP-7 the callus density increased in both cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20838755     DOI: 10.1007/s00113-010-1815-7

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  24 in total

1.  Expression of basic fibroblast growth factor during distraction osteogenesis.

Authors:  H Y Yeung; S K Lee; K P Fung; K S Leung
Journal:  Clin Orthop Relat Res       Date:  2001-04       Impact factor: 4.176

2.  Nuclear fusion of signaling pathways.

Authors:  R Janknecht; T Hunter
Journal:  Science       Date:  1999-04-16       Impact factor: 47.728

3.  Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions.

Authors:  G E Friedlaender; C R Perry; J D Cole; S D Cook; G Cierny; G F Muschler; G A Zych; J H Calhoun; A J LaForte; S Yin
Journal:  J Bone Joint Surg Am       Date:  2001       Impact factor: 5.284

4.  [Clinical experience with bone morphogenetic protein 7 (BMP 7) in nonunions of long bones].

Authors:  G Zimmermann; A Moghaddam; C Wagner; B Vock; A Wentzensen
Journal:  Unfallchirurg       Date:  2006-07       Impact factor: 1.000

5.  Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model.

Authors:  M F Sciadini; K D Johnson
Journal:  J Orthop Res       Date:  2000-03       Impact factor: 3.494

6.  Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report.

Authors:  Darko Anticevic; Mislav Jelic; Slobodan Vukicevic
Journal:  J Pediatr Orthop B       Date:  2006-05       Impact factor: 1.041

7.  Pharmacokinetics and tissue distribution of recombinant human transforming growth factor beta 1 after topical and intravenous administration in male rats.

Authors:  T F Zioncheck; S A Chen; L Richardson; M Mora-Worms; C Lucas; D Lewis; J D Green; J Mordenti
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

8.  Acceleration of regenerate ossification during distraction osteogenesis with recombinant human bone morphogenetic protein-7.

Authors:  Yoshihiko Mizumoto; Timothy Moseley; Michael Drews; Virgil N Cooper; A Hari Reddi
Journal:  J Bone Joint Surg Am       Date:  2003       Impact factor: 5.284

9.  A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair.

Authors:  Thomas A Einhorn; Robert J Majeska; Ahamed Mohaideen; Eric M Kagel; Mary L Bouxsein; Thomas J Turek; John M Wozney
Journal:  J Bone Joint Surg Am       Date:  2003-08       Impact factor: 5.284

10.  Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates.

Authors:  S D Cook; M W Wolfe; S L Salkeld; D C Rueger
Journal:  J Bone Joint Surg Am       Date:  1995-05       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.